Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/AMGN
icon
Up to 4x
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Amgen, Inc. (AMGN) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Amgen (AMGN) trades at $414.87, up 0.43% with a bullish technical signal. The stock shows strong fundamentals with 2025 revenue of $36.75B and net income of $7.71B, supported by consistent earnings beats. Recent positive Phase 3 results for dazodalibep in Sjögren's disease highlight pipeline progress. Valuation metrics include P/E of 25.31 and ROE of 91.47%, though high debt levels warrant monitoring.
Outlook remains positive with analyst consensus at Buy (53.66%) and a $403.79 price target. Key opportunities include robust cash flow and therapeutic diversification, while risks involve acquisition debt and competitive pressures in biotech. The stock's current price near 52-week highs reflects investor confidence in growth prospects.
Read full analysis

Key Stats

  • Market Cap
    $220.28B
  • Volume
    2,365,324
  • Sector
    Health
  • 52W High
    $444.12
  • 52W Low
    $290.13
  • Typical Hold Time
    72 Days
  • Enterprise Value
    $263.59B
  • Div Yield
    2.47%
  • Trading Activity
    87% Sell | 13% Buy
$414.87
52W Low: $290.13
10 Oct 2025
52W High: $444.12
03 Sep 2026

Track Amgen, Inc. (AMGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Amgen, Inc. has traded between a low of $290.13 and a high of $444.12, highlighting its annual price range. Buy and sell Amgen, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Most Recent News

Content is generated by Aura AI

New data supports Furoscix ReadyFlow autoinjector for outpatient edema management in heart failure and CKD.

MannKind presented new clinical data at HFSA 2026 showing that Furoscix ReadyFlow, an autoinjector delivering subcutaneous furosemide, provides diuretic effects comparable to IV administration for treating edema in heart failure and chronic kidney di...

Market News
1 hour ago
Mannkind Corporation
Bullish
news icon
New data supports Furoscix ReadyFlow autoinjector for outpatient edema management in heart failure and CKD.

Class action lawsuit filed against Millrose Properties over undisclosed $200M property leases causing stock drop

A securities class action lawsuit was filed against Millrose Properties, Inc. for allegedly misleading investors by not disclosing that it would lease $200 million worth of properties purchased from Lennar at a loss. The lawsuit claims Millrose misre...

Market News
1 hour ago
Gainey Mckenna & Egleston
Bearish
news icon
Class action lawsuit filed against Millrose Properties over undisclosed $200M property leases causing stock drop

MindWave signs 3 deals to build blockchain networks in climate finance, sports media, and insurance sectors.

MindWave Innovations Inc., a subsidiary of Apimeds Pharmaceuticals US, signed three agreements within 10 days to create dedicated blockchain networks for clients in climate finance, sports media, and insurance. Each network runs on MindWave's MindCha...

Market News
3 hours ago
Ibn
Bullish
news icon
MindWave signs 3 deals to build blockchain networks in climate finance, sports media, and insurance sectors.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $220.28B
  • Volume
    2,365,324
  • Sector
    Health
  • 52W High
    $444.12
  • 52W Low
    $290.13
  • Typical Hold Time
    72 Days
  • Enterprise Value
    $263.59B
  • Div Yield
    2.47%
  • Trading Activity
    87% Sell | 13% Buy
$414.87
52W Low: $290.13
10 Oct 2025
52W High: $444.12
03 Sep 2026

Track Amgen, Inc. (AMGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Amgen, Inc. has traded between a low of $290.13 and a high of $444.12, highlighting its annual price range. Buy and sell Amgen, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!